Figures & data
Figure 1. Patient factors for (a) apixaban (all prescribers), (b) apixaban (GP/specialist subgroups), and (c) rivaroxaban (all prescribers), inappropriate underdoses from the clinical vignette survey.
Figure 2. Self-reported (a) Understanding of DOAC guidelines and approach, (b) Perception of DOAC dosing confidence, and (c) Perception of DOAC underdose risk, all respondents (N=335; 150 GPs, 185 specialists), derived from the physician survey.
Table 1. Demographics, characteristics, and comparison of prescribers who selected no and ≥1 inappropriate underdose(s)* (N = 336; 150 GPs, 186 specialists).
Table 2. Comparison of key prescriber demographics or characteristics by no or ≥1 inappropriate underdose decisions (t-test).
Table 3. Key characteristics of survey participants by specialty×.
Figure 3. Schematic of main characteristics* associated with inappropriate underdosing of DOACs.
